Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH2)2[CuCl4]

NANCY MARTINI, JULIANA E. PARENTE, JUAN JOSÉ MARTÍNEZ MEDINA, GUSTAVO A. ECHEVERRÍA, OSCAR E. PIRO, LUIS LEZAMA, PATRICIA A.M. WILLIAMS, EVELINA G. FERRER; MARIA EUGENIA TOLEDO, GRACIELA E. ESCUDERO, CARLOS H. LAINO

JOURNAL OF INORGANIC BIOCHEMISTRY

ELSEVIER SCIENCE INC

Lugar: Amsterdam; Año: 2017 vol. 174 p. 76 - 76

0162-0134

n the current study the ability of copper complex to exert multiple biological activities is combined with the pharmacological action of sertraline, a well recognized antidepressant drug which also denotes antinociceptive activity. The hydrated and anhydrous forms of the tetrachlorocuprates(II) salts, namely (SerH2)2[CuCl4].½H2O and (SerH2)2[CuCl4], were synthesized and characterized by FTIR, EPR, and UV-visible spectroscopies. Their crystal structures were determined by X-ray diffraction methods. The hydrate crystallizes in the monoclinic P21 space group with a=8.0807(2) Å, b=36.2781(8) Å, c=12.6576(3) Å, β=95.665(2)º, and Z=4 molecules per unit cell and the un-hydrate also in P21 with a=13.8727(6) Å, b=7.5090(3) Å, c=18.618(1) Å, β=104.563(6)º, and Z=2. Solution studies show that both compounds contain the same bioactive species. It has been suggested that Cu(II) might be critical in the development of mood disorders, has potent biocidal activity, and also act as analgesic